The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
Animals
Brain
/ drug effects
Bridged-Ring Compounds
/ pharmacology
Cell Line
Disease Models, Animal
Dopaminergic Neurons
/ drug effects
Humans
Male
Mice
Multiple System Atrophy
/ drug therapy
Neuroprotective Agents
/ pharmacology
Organophosphates
/ pharmacology
Protein Aggregation, Pathological
/ drug therapy
alpha-Synuclein
/ metabolism
Aggregation
Glial cytoplasmic inclusions
Mouse model
Multiple system atrophy
Neuropathology
Oligomersation
Seeding
Synucleinopathy
Journal
Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730
Informations de publication
Date de publication:
01 11 2019
01 11 2019
Historique:
received:
22
01
2019
revised:
09
07
2019
accepted:
12
07
2019
pubmed:
19
7
2019
medline:
27
5
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
Multiple system atrophy (MSA) is a fatal, adult-onset neurodegenerative disorder that has no cure and very limited treatment options. MSA is characterized by deposition of fibrillar α-synuclein (α-syn) in glial cytoplasmic inclusions in oligodendrocytes. Similar to other synucleinopathies, α-syn self-assembly is thought to be a key pathologic event and a prominent target for disease modification in MSA. Molecular tweezers are broad-spectrum nanochaperones that prevent formation of toxic protein assemblies and enhance their clearance. The current lead compound, CLR01, has been shown to inhibit α-syn aggregation but has not yet been tested in the context of MSA. To fill this gap, here, we conducted a proof-of-concept study to assess the efficacy of CLR01 in remodeling MSA-like α-syn pathology in the PLP-α-syn mouse model of MSA. Six-month-old mice received intracerebroventricular CLR01 (0.3 or 1 mg/kg per day) or vehicle for 32 days. Open-field test revealed a significant, dose-dependent amelioration of an anxiety-like phenotype. Subsequently, immunohistochemical and biochemical analyses showed dose-dependent reduction of pathological and seeding-competent forms of α-syn, which correlated with the behavioral phenotype. CLR01 treatment also promoted dopaminergic neuron survival in the substantia nigra. To our knowledge, this is the first demonstration of an agent that reduces formation of putative high-molecular-weight oligomers and seeding-competent α-syn in a mouse model of MSA, supporting the view that these species are key to the neurodegenerative process and its cell-to-cell progression in MSA. Our study suggests that CLR01 is an attractive therapeutic candidate for disease modification in MSA and related synucleinopathies, supporting further preclinical development.
Identifiants
pubmed: 31319154
pii: S0925-4439(19)30230-3
doi: 10.1016/j.bbadis.2019.07.007
pmc: PMC8425273
mid: NIHMS1732855
pii:
doi:
Substances chimiques
Bridged-Ring Compounds
0
CLR01 compound
0
Neuroprotective Agents
0
Organophosphates
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
165513Subventions
Organisme : Austrian Science Fund FWF
ID : I 2102
Pays : Austria
Organisme : NIA NIH HHS
ID : R01 AG050721
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI028697
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Acc Chem Res. 2004 Jun;37(6):357-64
pubmed: 15196045
Neuropathol Appl Neurobiol. 2016 Feb;42(1):20-32
pubmed: 26785838
Nat Neurosci. 2015 Oct;18(10):1394-404
pubmed: 26404714
Neurology. 2015 Aug 4;85(5):404-12
pubmed: 26138942
J Am Chem Soc. 2011 Oct 26;133(42):16958-69
pubmed: 21916458
J Neural Transm (Vienna). 2010 Mar;117(3):369-75
pubmed: 20091064
Neurotherapeutics. 2017 Oct;14(4):1107-1119
pubmed: 28585223
J Neurochem. 2016 May;137(3):331-59
pubmed: 26852372
Brain. 2012 Dec;135(Pt 12):3735-48
pubmed: 23183235
Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9593-8
pubmed: 27482103
Front Neurosci. 2016 Mar 10;10:99
pubmed: 27013960
Methods Mol Biol. 2012;849:11-21
pubmed: 22528080
Curr Pharm Des. 2014;20(15):2469-83
pubmed: 23859557
Environ Health Perspect. 2016 Nov;124(11):1766-1775
pubmed: 27301718
Chem Commun (Camb). 2016 Oct 15;52(76):11318-34
pubmed: 27546596
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6020-4
pubmed: 10339534
Exp Neurobiol. 2014 Dec;23(4):324-36
pubmed: 25548532
Neurotherapeutics. 2012 Apr;9(2):464-76
pubmed: 22373667
Acta Neurol Scand. 2018 Jan;137(1):33-37
pubmed: 28748633
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376-85
pubmed: 25261551
J Am Chem Soc. 2008 Jul 30;130(30):9824-8
pubmed: 18605724
Front Neurosci. 2016 Jan 29;10:12
pubmed: 26858591
Mol Neurodegener. 2015 Mar 19;10:10
pubmed: 25886309
EMBO Rep. 2002 Jun;3(6):583-8
pubmed: 12034752
Acta Neuropathol. 2012 Jul;124(1):37-50
pubmed: 22370907
Amyloid. 2005 Jun;12(2):88-95
pubmed: 16011984
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5308-17
pubmed: 26324905
Behav Brain Res. 2017 Aug 30;333:150-160
pubmed: 28668282
Anal Biochem. 1994 Mar;217(2):220-30
pubmed: 8203750
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47
pubmed: 23898162
J Neurochem. 2016 Jan;136(1):172-85
pubmed: 26465922
N Engl J Med. 2015 Jan 15;372(3):249-63
pubmed: 25587949
Acta Neuropathol Commun. 2018 Jan 3;6(1):2
pubmed: 29298733
Exp Neurol. 2016 Apr;278:105-15
pubmed: 26854933
J Biol Chem. 2014 Apr 11;289(15):10727-10737
pubmed: 24567327